Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0955 |
---|---|
High | 0.0955 |
Low | 0.0955 |
Bid | 0.095 |
Offer | 0.106 |
Previous close | 0.0835 |
Average volume | 24.51k |
---|---|
Shares outstanding | 96.00m |
Free float | 29.19m |
P/E (TTM) | -- |
Market cap | 10.22m USD |
EPS (TTM) | -0.0667 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 07:10 BST.
More ▼
Announcements
- Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
- Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
- Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
- Conduit Pharmaceuticals to Join Russell 3000® Index
- Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
- Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub
- Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference
- Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656
More ▼